Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $24
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $20 to $24.
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $20 to $24.